Industry News
Biotechnology Industry News
Novo Nordisk is gearing up to…
Novo Nordisk is gearing up to submit its rare blood disorder drug to the FDA after the former Forma Therapeutics asset reduced a painful complication of sickle cell disease (SCD) in a phase 3 study.
A phase 2 trial combining…
A phase 2 trial combining Agenus’ and MiNK Therapeutics’ cancer candidates has missed its primary endpoint. But with the study generating early evidence the cocktail improves survival, the biotechs said the data support further assessment
President Donald Trump has ordered…
President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push to clear barriers to access to treatments for serious mental illnesses.
In another sign that the biotech…
In another sign that the biotech IPO market is heating back up, Odyssey Therapeutics has made a fresh announcement of its intention to go public.
After dropping headline-grabbing…
After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib, last Monday, Revolution Medicines is not resting on its laurels. The Bay Area biotech spent several recent days in San Diego highlighting earlier
Asked by Fierce if he’d consider…
Asked by Fierce if he'd consider returning to the FDA, Pazdur said he wouldn't serve again under the Trump administration "for obvious reasons."
The agreement fulfills several…
The agreement fulfills several ambitions for UCB. Besides building its epilepsy position, it "marks a strategic expansion into regenerative medicine and advanced therapies," the Belgian biopharma explained.
More than a year after licensing…
More than a year after licensing its PD-1xVEGF bispecific, Merck & Co. has finally unveiled the first clinical data from the antibody. The results suggest the drug boasts similar safety and efficacy in non-small cell
Following its recently announced…
Following its recently announced partnership with Novo Nordisk, OpenAI is introducing a new reasoning model, GPT-Rosalind, to support research in biology, drug discovery and translational medicine.
Kailera Therapeutics appears to…
Kailera Therapeutics appears to have set a new benchmark for biotech IPOs with an upsized $625 million offering to fund its pipeline of obesity therapies.
After helping guide Metsera…
After helping guide Metsera through its high-profile, $10 billion acquisition by Pfizer last year, Matthew Lang is swinging over to a different obesity biotech as chief operating officer and general counsel at Structure Therapeutics.
The traditional gold standard of…
The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundreds of patients has inherently been unfeasible for the rare disease community.
With a few chemical tweaks and…
With a few chemical tweaks and some dutiful protein partners, a new biotech from Flagship Pioneering thinks it has cracked the code to turn DNA into a brand-new class of therapeutics.
China’s biotech rise has been a…
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma executives. But to Roivant CEO Matt Gline, the country is nothing more than a red herring.
Learn how early intervention can…
Learn how early intervention can help drug developers convert suboptimal formulations into scalable, clinically viable solutions.
After its bet on a rare eye…
After its bet on a rare eye disease gene therapy ended in a phase 3 fail, Johnson & Johnson is returning the asset to sender as MeiraGTx buys back back full rights to botaretigene sparoparvovec
Storm Therapeutics has closed a…
Storm Therapeutics has closed a $56 million series C financing and launched a Phase 2 trial of its lead asset for sarcoma patients.
Aligos Therapeutics has secured a…
Aligos Therapeutics has secured a $25 million upfront fee from hepatology biopharma Amoytop in exchange for the China rights to its phase 2-stage chronic hepatitis B virus (HBV) treatment.
A slow start to 2026 has put…
A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing the already limited funding opportunities available for startups.
In a complex therapeutic…
In a complex therapeutic landscape, WuXi AppTec is simplifying the path from discovery to patient. Find out how.